Newsroom

September 2019

• Press release Sep 30, 2019

  Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma

  Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program,…
• Press release Sep 30, 2019

  Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma

  Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2]  IRIDIUM is largest study in Phase III PLATINUM clinical…
• Ad hoc release Sep 29, 2019

  Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients

  In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only…
• Featured News Sep 27, 2019

  European Patient Innovation Summit recommends increasing the impact of digital technologies

  European Patient Innovation Summit publishes a position paper on Digital Health from a Patient Perspective with recommendations on digital health.

• 
  Story Sep 26, 2019 From Our Labs

  Seeing through knees in quest to alleviate osteoarthritis

  Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.

• Featured News Sep 24, 2019

  AveXis data integrity - updates

• Press release Sep 19, 2019

  AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

  New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gainUpdated results from global…
• Press release Sep 18, 2019

  Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin

  Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2] The landmark VERIFY study is…
• Ad hoc release Sep 17, 2019

  Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis

  Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has…
• Press release Sep 13, 2019

  Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

  Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20…
• Press release Sep 13, 2019

  New Novartis data show that neuronal and glial filaments, biomarkers of disease activity, have the potential to support decision making in the management of multiple sclerosis (MS) patient

  Monitoring disease activity and treatment effectiveness in MS patients in real-time is a serious challenge for physicians  New data show how the use of two central nervous system-derived…
• Press release Sep 12, 2019

  New Novartis data show Mayzent® can help preserve mobility for longer in patients with secondary progressive multiple sclerosis (SPMS)

  New post hoc statistical analysis of the pivotal EXPAND study at ECTRIMS shows that Mayzent® (siponimod) can help patients keep their mobility for over four years longer on average *[1] …